Tag Archives: Valeant Pharmaceuticals International Inc.

Update: CDC data say docs still making billions from Pharma, med device companies; my personal take.

The News: It’s been a few years since the US government unveiled its Open Payments (OP) database, a collection of drug and device makers’ payments to healthcare providers. The data-collection… Read more »

FDA chief Gottlieb makes good on promise to increase drug price competition; will expedite review of generics

The Food and Drug Administration on Tuesday (June 27, 2017) moved to try to spur more competition in the market for generic drugs, an effort aimed at driving down prices. In… Read more »

Reasons why Valeant/Ackman divorce better than staying in a bad marriage

Steve’s Take: [“Life is far too short to spend it immersed in an unhealthy relationship.”—Jeffrey M. Cohen, Esq., professional mediator.] This week (March 13, 2017), billionaire Bill Ackman exited one… Read more »

Valeant CEO tries to paint happy face on 4Q results; markets not buying the turnaround–yet?

The News: Valeant Pharmaceuticals International Inc.’s (Laval Quebec) fourth-quarter loss widened to $515 million versus $385 million in the same period of 2015, as sales plummeted 13% year-over-year to $2.4… Read more »

Valeant divests assets worth $2.1 billion to ease debt load; finally a smart move, but too little, too late?

Valeant Pharmaceuticals International Inc. (Laval Quebec) is selling its Dendreon cancer treatment business and three skincare brands for $2.12 billion as the troubled Canadian drugmaker looks to reduce more than… Read more »

Valeant to keep Salix after Takeda deal blows up; it’s déjà vu all over again

Valeant Pharmaceuticals International Inc.’s (Laval Québec) talks to sell a stomach-drug business to Japan’s Takeda Pharmaceutical Co. (Osaka) for roughly $10 billion have broken down amid last-minute disagreements over price and other matters,… Read more »

Arrowhead Pharma obliterated after ditching Hep B candidate; oh, that’s right, biotechs are risky

Shares of Arrowhead Pharmaceuticals Inc. (Pasadena CA) cratered 69% to $1.44 last week (November 28 to December 2, 2016) after the company said it would stop developing all drugs being… Read more »

Former Valeant and Philidor executives charged in kickback scheme; how management got fooled, or so they say

Federal prosecutors filed charges against former Valeant Pharmaceuticals International Inc. (Laval Québec) executive Gary Tanner and former Philidor Rx Services LLC (Hatboro PA) CEO Andrew Davenport, alleging they engaged in… Read more »

Valeant stock plunges anew on dismal 3Q results; behold another pharma Sisyphus

After an already noisy year, Valeant Pharmaceuticals International Inc. (Laval Québec) once again took investors off guard–this time, on Election Day–as new management cut the annual profit forecast to well… Read more »

Needing cash, Valeant in talks to sell stomach-drug unit in $10 billion deal; hedge-fund icon Bill Ackman finally has a good day

Valeant Pharmaceuticals International Inc. (Laval Quebec) is in advanced talks to sell a big stomach-drug business to Japan’s Takeda Pharmaceutical Co. for about $10 billion, a move seen easing pressure on Valeant over its… Read more »